The agreement will give Genentech access to Sangamo’s capsid delivery platform and epigenetic regulation technology with applications in neurodegenerative disease.
In a significant move set to reshape the landscape of drug discovery, NovAliX, a leading Contract Research Organization (CRO) specializing in drug development, has entered a strategic partnership with Bruker, a global leader in scientific instruments.
